2-TUR NATRIY-GLYUKOZA KOTRANSPORTYORI INGIBITORLARINI QO‘LLASHDA JIGAR FIBROZ KO‘RSATKICHLARI VA INSULINGA REZISTENTLIK DINAMIKASI
##article.subject##:
2-tip qandli diabet, MAYJK, SGLT-2 ingibitorlari, Fib-4, jigar fibrozi, NAFLD fibroz indeksi, insulin rezistentlik##article.abstract##
Ushbu tadqiqotda 2-tip qandli diabet bilan og‘rigan bemorlarda NGLT-2 ingibitorlarini qo‘llash fonida jigar fibroz ko‘rsatkichlari (Fib-4, NAFLD fibrosis score) va insulinga rezistentlik indeksi (HOMA-IR) ning o‘zgarishi hamda ular o‘rtasidagi o‘zaro bog‘liqlik baholandi. Tadqiqot davomida 150 nafar bemor kuzatildi, ulardan eksperimental guruhdagilarga SGLT-2 ingibitori buyurildi. Fib-4, NFS va HOMA-IR indekslari davolashdan oldin va 6 oydan so‘ng qayta baholandi.Statistik tahlil natijalariga ko‘ra, NGLT-2 ingibitorlarini qo‘llash fonida Fib-4 va NFS indekslarida ishonchli pasayish kuzatildi (p < 0.05), HOMA-IR darajasi bilan Fib-4 va NFS o‘rtasida esa aniq ijobiy korrelyatsiya qayd etildi (ρ > 0.85; p < 0.001).Olingan natijalar NGLT-2 preparatlarining nafaqat glyukozani nazorat qiluvchi, balki metabolik va gepatoprotektor xususiyatlarga ham ega ekanligini tasdiqlaydi.
Библиографические ссылки
Eslam M. et al. "MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease." J Hepatol, 2020.
Younossi Z.M. et al. "Global epidemiology of NAFLD." Hepatology, 2016.
Dulai P.S. et al. "Increased risk of mortality by fibrosis stage in NAFLD: Systematic review and meta-analysis." Hepatology, 2017.
European Association for the Study of the Liver (EASL). "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis." J Hepatol, 2021.
Takahashi H. et al. "Empagliflozin improves liver steatosis and fibrosis in type 2 diabetes patients with NAFLD." Diabetes Care, 2020.
Kuchay M. et al. "Dapagliflozin in the treatment of NAFLD in patients with type 2 diabetes." Diabetes Care, 2018.
Sattar N., McGuire D.K. "SGLT2 inhibitors and cardiovascular risk: Lessons from large outcome trials." Lancet Diabetes Endocrinol, 2019.
Sterling R.K. et al. "Development of a simple noninvasive index to predict significant fibrosis in patients with NAFLD." Hepatology, 2006.
Angulo P. et al. "The NAFLD fibrosis score: A noninvasive system to identify patients with liver fibrosis." Hepatology, 2007.
Matthews D.R. et al. "Homeostasis model assessment: insulin resistance and beta-cell function." Diabetologia, 1985.
